Does Weight Loss
Equal Health?
One clinician's case against the GLP-1 drugs, built on a single principle: nothing is free in biology.
There is no real debate that GLP-1 drugs cause weight loss. Dr. Schuster's argument is that the right question was never “does it work,” but “is the reward worth the cost.” His answer turns on one mechanism, and one rule he repeats: nothing in the body comes for free.
How a GLP-1 drug quiets hunger
GLP-1 (glucagon-like peptide-1) is a real signal your gut releases when you eat. The drugs amplify it. Following the pathway from his slide:
You eat carbs and fats. The gut's L-cells release GLP-1; the vagus nerve signals the brain.
In the brain (the hypothalamic PVN), GLP-1 increases sympathetic outflow, the “fight-or-flight” branch of the nervous system.
The body reads that as “full and stressed”: digestion slows, appetite drops. You eat less, and you lose weight.
His point: the appetite suppression is not a clean, free benefit. It is a downstream effect of raising sympathetic tone, and that same lever moves everything else.
↑ Heart rate
Sympathetic activation raises resting HR.
↑ Blood pressure
Vascular tone rises with it.
↑ Stress hormones
Corticosterone and the stress axis engage.
↑ Muscle sympathetic activity
Measured as elevated MSNA.
Why he compares it to cocaine
This is the line that gets attention, so it is worth stating precisely. Dr. Schuster is not claiming GLP-1 drugs are illegal, addictive, or as dangerous as cocaine. His analogy is narrow and mechanistic: both, he argues, chronically elevate sympathetic tone, and both produce weight loss largely because a body running in that state eats less. His conclusion is that appetite suppression driven by raising “fight-or-flight” activity is, over the long term, the opposite of what a stressed physiology needs.
The people taking it are already over-revved
Here is the heart of his case. He argues that carrying excess weight almost always comes with chronic sympathetic nervous system hyperactivity, and that this over-activation is, in his framing, a common thread running through a large share of chronic mental and physical disease.
If that is true, then a drug whose mechanism is to push sympathetic tone even higher is, in his words, exactly the wrong direction for someone whose real goal is health rather than a smaller number on the scale.
“Nothing is free in biology. You lose weight because you eat less, but the long-term costs can outweigh the benefit.”— Dr. Jason Schuster, on the risk-versus-reward of GLP-1 drugs
What the trials actually show
Honest context
Fairness matters here. The mechanism Dr. Schuster describes (GLP-1 raising sympathetic activity) is documented in the physiology literature. But the leap from “raises sympathetic tone” to “net harmful” is his interpretation, and the clinical outcomes are more mixed than the analogy suggests.
Notably, the SELECT trial (Nature Medicine, 2024), one of the papers cited in his own slide, found that semaglutide reduced major cardiovascular events in overweight and obese adults without diabetes. GLP-1 drugs are FDA-approved for type 2 diabetes and obesity, and for many patients the documented benefits are substantial.
So read this as a genuine scientific tension worth understanding, not a settled verdict: a real mechanistic concern on one side, real trial outcomes on the other. Your own doctor knows your situation; a webpage does not.
- SELECT trial. Long-term weight-loss effects of semaglutide in obesity without diabetes. Nature Medicine, 2024.
- GLP / GLP-1R dual-agonist therapies for diabetes and weight loss: chemistry, physiology, clinical applications. Cell Metabolism, Vol. 35, Sept 2023.
- The physiological role of the brain GLP-1 system in stress. Cogent Biology, 2016.
Go deeper than the summary
Dr. Schuster's board-certified, accredited nutrition and metabolism courses: the full argument, the physiology, and the sources.